ES2138618T3 - Esteroides 17-sustituidos utiles en el tratamiento del cancer. - Google Patents

Esteroides 17-sustituidos utiles en el tratamiento del cancer.

Info

Publication number
ES2138618T3
ES2138618T3 ES93906670T ES93906670T ES2138618T3 ES 2138618 T3 ES2138618 T3 ES 2138618T3 ES 93906670 T ES93906670 T ES 93906670T ES 93906670 T ES93906670 T ES 93906670T ES 2138618 T3 ES2138618 T3 ES 2138618T3
Authority
ES
Spain
Prior art keywords
carbon atoms
beta
hydrogen atom
pyridyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906670T
Other languages
English (en)
Inventor
Susan Elaine Barrie
Michael Jarman
Gerard Andrew Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2138618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929207057A external-priority patent/GB9207057D0/en
Priority claimed from GB929224880A external-priority patent/GB9224880D0/en
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of ES2138618T3 publication Critical patent/ES2138618T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA GENERAL (I) EN LA QUE X REPRESENTA EL RESIDUO DE LOS ANILLOS A, B Y C DE UN ESTEROIDE, R REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO DE ALQUILO DE ENTRE 1 Y 4 ATOMOS DE CARBONO, R14 REPRESENTA UN ATOMO DE HIDROGENO Y R15 REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO DE ALQUIL O DE ALCOXIDO DE ENTRE 1 Y 4 ATOMOS DE CARBONO, O UN GRUPO DE HIDROXIDO O DE ALQUILCARBONILOXIDO DE ENTRE 2 Y 5 ATOMOS DE CARBONO O R14 Y R15 JUNTAS REPRESENTAN UN DOBLE ENLACE Y R16 REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO DE ALQUIL DE ENTRE 1 Y 4 ATOMOS DE CARBONO EN FORMA DE BASES LIBRES O DE SALES DE ADICION ACIDA FARMACOLOGICAMENTE ACEPTABLES, CON LA SALVEDAD DE QUE EL 17-(3-PIRIDIL)ANDROSTA-5,14,16TRIEN-3(BETA)-OL Y 15(BETA)-ACETOXI-17-(3-PIRIDIL)ANDROSTA-5,16-DIEN-3(BETA)-OL Y SUS 3-ACETATOS Y EL 3(BETA)-METOXI-17-(3-PIRIDIL)ANDROS-16-ENE SON RECLAMADOS SOLAMENTE PARA SU USO EN LA TERAPIA, LOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DEPENDIENTES DE LOS ANDROGENOS, ESPECIALMENTE DEL CANCER PROSTATICO, Y TAMBIEN DE LAS ENFERMEDADES DEPENDIENTES DE LOS ESTROGENOS TALES COMO EL CANCER DE PULMON.
ES93906670T 1992-03-31 1993-03-15 Esteroides 17-sustituidos utiles en el tratamiento del cancer. Expired - Lifetime ES2138618T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207057A GB9207057D0 (en) 1992-03-31 1992-03-31 Steroids
GB929224880A GB9224880D0 (en) 1992-11-27 1992-11-27 Steroids

Publications (1)

Publication Number Publication Date
ES2138618T3 true ES2138618T3 (es) 2000-01-16

Family

ID=26300621

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906670T Expired - Lifetime ES2138618T3 (es) 1992-03-31 1993-03-15 Esteroides 17-sustituidos utiles en el tratamiento del cancer.

Country Status (16)

Country Link
EP (1) EP0633893B1 (es)
JP (1) JP2742331B2 (es)
KR (1) KR100235135B1 (es)
AT (1) ATE186913T1 (es)
AU (1) AU668144B2 (es)
CA (1) CA2132449C (es)
CZ (1) CZ287434B6 (es)
DE (2) DE69327096T2 (es)
DK (1) DK0633893T3 (es)
ES (1) ES2138618T3 (es)
GB (1) GB2265624B (es)
IL (1) IL105078A (es)
LU (1) LU91911I2 (es)
MX (1) MX9301525A (es)
NZ (1) NZ249911A (es)
WO (1) WO1993020097A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU676088B2 (en) * 1993-09-30 1997-02-27 British Technology Group Limited Synthesis of 17-(3-pyridyl) steroids
WO1995011914A1 (en) * 1993-10-27 1995-05-04 Merrell Pharmaceuticals Inc. Δ16 unsaturated c¿17? heterocyclic steroids useful as steroid c17-20 lyase inhibitors
KR100809899B1 (ko) 2000-11-17 2008-03-10 다케다 야쿠힌 고교 가부시키가이샤 신규 이미다졸 유도체, 이의 제조 방법 및 이의 용도
AU2002214320A1 (en) 2000-11-20 2002-05-27 Takeda Chemical Industries Ltd. Imidazole derivatives, process for their preparation and their use
EP1348706B1 (en) 2000-12-08 2009-08-19 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
CA2470214A1 (en) * 2001-12-13 2003-06-26 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
EP2298315A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
ES2377074T3 (es) * 2004-08-24 2012-03-22 Btg International Limited Procedimiento para la preparación de 17-vinil-triflatos como intermedios
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
ES2428634T3 (es) 2006-08-25 2013-11-08 Janssen Oncology, Inc. Composiciones para el tratamiento del cáncer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
CA2761389A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
SG176105A1 (en) 2009-06-26 2011-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US20120282331A1 (en) * 2009-11-13 2012-11-08 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
WO2011088160A2 (en) * 2010-01-15 2011-07-21 Biomarin Pharmaceutical Inc. Novel cyp17 inhibitors
MX345788B (es) 2010-08-04 2017-02-15 Pellficure Pharmaceuticals Inc * Nuevo tratamiento del carcinoma de prostata.
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
TW201307378A (zh) * 2010-12-16 2013-02-16 Biomarin Pharm Inc Ｃｙｐ１１ｂ、ｃｙｐ１７及／或ｃｙｐ２１抑制劑
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
CN102321142A (zh) * 2011-09-29 2012-01-18 重庆医药工业研究院有限责任公司 一种醋酸阿比特龙晶型及其制备方法
DE102011083725A1 (de) * 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2013053691A1 (en) 2011-10-10 2013-04-18 Zach System Process for preparing 17-substituted steroids
CN103059090B (zh) * 2011-10-20 2016-06-22 连云港润众制药有限公司 醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法
LT2785349T (lt) 2011-11-30 2019-12-10 Astrazeneca Ab Kombinuotas vėžio gydymas
EP2607371A1 (en) 2011-12-23 2013-06-26 Crystal Pharma, S.A.U. Processes for the preparation of abiraterone and related compouds
CN103172690B (zh) * 2011-12-23 2016-08-24 重庆医药工业研究院有限责任公司 醋酸阿比特龙及其中间体的制备方法
CN105461777B (zh) * 2012-01-04 2017-07-18 连云港润众制药有限公司 一种醋酸阿比特龙的纯化方法
CN103254265B (zh) 2012-02-21 2016-07-13 上海希迈医药科技有限公司 醋酸阿比特龙三氟乙酸盐及其制备方法和应用
CN102627681B (zh) * 2012-03-23 2016-04-13 山东新时代药业有限公司 一种醋酸阿比特龙的制备方法
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013159225A1 (en) * 2012-04-23 2013-10-31 Alphora Research Inc. Process for preparation of 17-substituted steroids
JP2015518888A (ja) 2012-06-06 2015-07-06 ノバルティス アーゲー 腫瘍疾患を治療するための１７−アルファ−ヒドロキシラーゼ（ｃ１７，２０−リアーゼ）インヒビターと特定のｐｉ−３ｋインヒビターとの組み合わせ
CN102731605B (zh) * 2012-06-19 2016-04-13 鲁南制药集团股份有限公司 一种醋酸阿比特龙的纯化方法
JP6196302B2 (ja) * 2012-07-10 2017-09-13 バイエル・ファルマ・アクティエンゲゼルシャフト ３−置換エストラ−１，３，５（１０），１６−テトラエン誘導体、その調製法、これらを含む医薬製剤および医薬を調製するためのその使用
WO2014009437A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014016830A1 (en) * 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
ITMI20121788A1 (it) 2012-10-22 2014-04-23 Olon Spa Procedimento per la purificazione di abiraterone acetato
EP2917226A1 (en) 2012-11-09 2015-09-16 Synthon BV Process for making the 17-triflate intermediate of abiraterone-3-acetate
EP2917225A1 (en) 2012-11-09 2015-09-16 Synthon BV Process for making abiraterone-3-acetate
TWI570131B (zh) * 2012-11-13 2017-02-11 賽克系統公司 製備１７－經取代類固醇之方法
WO2014075978A1 (en) 2012-11-16 2014-05-22 Synthon B.V. Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound
CN103059091B (zh) * 2012-11-22 2017-04-19 常州靶点医药科技有限公司 一种避免重金属残留的醋酸阿比特龙的制备方法
CN103864878A (zh) * 2012-12-12 2014-06-18 天津大学 阿比特龙醋酸酯的制备方法
WO2014102833A2 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Process for abiraterone acetate
EP2968219B1 (en) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
EP2792682B1 (en) 2013-04-19 2016-11-09 Zach System Process for producing a solid form of abiraterone acetate
IN2013MU02133A (es) * 2013-06-24 2015-06-05 Sun Pharmaceutical Ind Ltd
ITMI20131861A1 (it) * 2013-11-08 2015-05-09 Ind Chimica Srl Processo per la preparazione di abiraterone e abiraterone acetato
US9676815B2 (en) 2013-07-29 2017-06-13 Industriale Chimica S.R.L. Process for the preparation of abiraterone or abiraterone acetate
EP3027638B1 (en) 2013-07-29 2017-12-27 Industriale Chimica S.R.L. Process for the preparation of abiraterone and abiraterone acetate
AU2014306698A1 (en) 2013-08-12 2016-01-28 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CN104558091B (zh) * 2013-10-16 2017-07-28 天津金耀集团有限公司 一种醋酸阿比特龙的合成方法
CA2938023C (en) 2014-01-28 2022-03-08 Olon S.P.A. Procedure for the preparation of abiraterone acetate and intermediates thereof
CN103965282B (zh) 2014-04-21 2016-01-20 武汉百科药物开发有限公司 一种醋酸阿比特龙的制备方法
US9315541B2 (en) 2014-05-20 2016-04-19 Olon S.P.A. Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives
EP3160450A1 (en) 2014-06-30 2017-05-03 Galenicum Health S.L. Stable pharmaceutical compositions in the form of immediate release tablets
CZ2014475A3 (cs) 2014-07-09 2016-01-20 Zentiva, K.S. Způsob přípravy Abirateron acetátu o vysoké čistotě aplikovatelný v průmyslovém měřítku
CA2960750A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
CA2969675C (en) 2014-12-05 2023-06-06 Aragon Pharmaceuticals, Inc. Anticancer compositions
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
US10519193B2 (en) 2016-02-02 2019-12-31 Shenzhen Targetrx, Inc. Steroidal compound, composition containing the same and use thereof
WO2017209939A1 (en) 2016-06-03 2017-12-07 Aragon Pharmaceuticals, Inc. Anticancer compositions
CA3044812A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione
EP3784218A1 (en) 2018-04-26 2021-03-03 Synthon B.V. Tablet compositions comprising abiraterone acetate
HU231297B1 (hu) 2018-07-31 2022-09-28 Richter Gedeon Nyrt Stabil gyógyszerkészítmények és eljárás az előállításukra
CN110272465A (zh) * 2019-07-15 2019-09-24 成都贝诺科成生物科技有限公司 阿比特龙衍生物、其制备方法与应用
MX2022001450A (es) 2019-08-08 2022-04-20 Laekna Ltd Metodo de tratamiento del cancer.
EP3854384A1 (en) 2020-01-27 2021-07-28 Adamed Pharma S.A. Pharmaceutical formulation comprising abiraterone acetate
CA3177123A1 (en) 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
WO2023148345A1 (en) 2022-02-04 2023-08-10 Janssen Pharmaceutica Nv Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
CN116917306A (zh) * 2022-02-18 2023-10-20 上海醇健医药技术有限公司 17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224288A (en) * 1987-04-22 1989-12-21 Merrell Dow Pharma 17b-(cyclopropylamino)androst-5-en-3b-ol and related compounds and methods using these for treatment of non-humans
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
ATE186913T1 (de) 1999-12-15
CZ233794A3 (en) 1995-02-15
AU3758493A (en) 1993-11-08
CA2132449C (en) 2002-09-10
DE69327096D1 (de) 1999-12-30
IL105078A (en) 1997-11-20
JPH07505377A (ja) 1995-06-15
GB2265624A (en) 1993-10-06
CA2132449A1 (en) 1993-10-14
DE122012000012I1 (de) 2012-06-14
LU91911I2 (fr) 2012-02-07
EP0633893B1 (en) 1999-11-24
DK0633893T3 (da) 2000-04-17
WO1993020097A1 (en) 1993-10-14
KR100235135B1 (ko) 2000-01-15
MX9301525A (es) 1994-02-28
EP0633893A1 (en) 1995-01-18
GB2265624B (en) 1995-04-19
CZ287434B6 (en) 2000-11-15
GB9305269D0 (en) 1993-05-05
JP2742331B2 (ja) 1998-04-22
DE69327096T2 (de) 2000-06-21
KR950700923A (ko) 1995-02-20
IL105078A0 (en) 1993-07-08
NZ249911A (en) 1996-06-25
AU668144B2 (en) 1996-04-26

Similar Documents

Publication Publication Date Title
ES2138618T3 (es) Esteroides 17-sustituidos utiles en el tratamiento del cancer.
RU2210574C2 (ru) Очищенные стероидсульфаматные соединения, эстрон-сульфаматы
GR3033524T3 (en) Steroids which inhibit angiogenesis.
SE7713341L (sv) Sett att framstella grenade och cykloalifatiska estrar ur androstan- och ostranserierna
KR880012633A (ko) C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물
JP2000509388A (ja) 抗炎症薬剤として有用なステロイドナイトレートエステル誘導体を含有する新規医薬組成物
PT88648A (pt) Process for the preparation of new androstane 17-carboxylic acid esters and a pharmaceutical composition containing same
DE2960689D1 (en) Fluorene and fluoranthene derivatives, process for their preparation and their therapeutic application
GB1038333A (en) Pharmaceutical compositions
US3637668A (en) N-substituted 4-aminosteroids
KR940701260A (ko) 스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법
ES439957A1 (es) Un procedimiento para la preparacion de d-homoesteroides de la serie del pregnano.
JPS5610200A (en) Anthracycline glycoside* its manufacture and medicinal composition containing same for tumor treatment
GB989881A (en) Improvements in or relating to 10 -methyl steroids and the production thereof
GB905845A (en) Steroid compounds and the preparation thereof
GB954146A (en) Improvements in or relating to steroid derivatives
ES403723A2 (es) Un procedimiento para la preparacion de esteroides de la serie del pregnano
GB961101A (en) Steroid compounds
TW343976B (en) 17-substituted steroids useful in cancer treatment
GB1063663A (en) Improvements in or relating to steroids and the manufacture thereof
GB1099008A (en) Novel unsaturated steroids, and processes for their preparation
GB1074468A (en) Carbalkoxyhtdrazones of the androstane adn estrane series
GB1101120A (en) 2-aminocarbonyl-3-amino-í¸-steroids
GR23003B (el) Μεθοδος δια την παραγωγην ωρισμενων παραγωγων τησσειρας του ανδροστανιου.
GB1113184A (en) The manufacture of 10ª‡-steroids

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633893

Country of ref document: ES